Launch of AB-Direct Phase 1 study - February 2021
The AB-Direct Phase 1 study, to investigate tissue distribution of novel antibiotic gepotidacin, has been launched at the beginning of February 2021 at the Department of Clinical Pharmacology, Medical University of Vienna, with INSERM as study Sponsor. This study involves an ex-vivo microdialysis procedure post-surgery. The first subjects for tonsillectomy and prostatectomy have been enrolled. Gepotidacin is currently in Phase 3 development by GSK as a potential treatment for uncomplicated urinary tract infection and uncomplicated gonorrhea.
